This is supported by the findings that RAS mutations are significantly enriched in cSCC arising in patients treated with vemurafenib relative to sporadic cSCC (Oberholzer et al., 2011; Su et al., 2012), and by the low rate of cSCC in patients treated with combined BRAFi and MEK inhibitor (MEKi) (Flaherty et al., 2012). The gene discussed is MAP2K7; the disease is skin squamous cell carcinoma.